---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| AADSM | American Academy of Dental Sleep Medicine |
| AASM | American Academy of Sleep Medicine |
| ABPM | Ambulatory blood pressure monitoring |
| ACP | American College of Physicians |
| ACS | Acute coronary syndrome |
| ADHD | Attention-deficit/hyperactivity disorder |
| AE | Adverse event |
| AF | Atrial fibrillation |
| AHFS | American Hospital Formulary Service |
| AHI | Apnea-hypopnea index |
| AHI3a | Apnea-hypopnea index based on hypopneas with at least 3% desaturation or arousal |
| AHI4 | Apnea-hypopnea index based on hypopneas with at least 4% oxygen desaturation |
| AHIAlt | Apnea-hypopnea index, AASM alternative hypopnea definition (at least 50% airflow reduction and at least 3% desaturation or arousal) |
| AHIChicago | Apnea-hypopnea index, Chicago criteria hypopnea definition |
| AHIRec | Apnea-hypopnea index, AASM recommended hypopnea definition (at least 30% airflow reduction and at least 4% desaturation) |
| AJRCCM | American Journal of Respiratory and Critical Care Medicine |
| APA | Asset purchase and license agreement |
| APAP | Auto-adjusting positive airway pressure (auto-PAP) |
| API | Active pharmaceutical ingredient; application programming interface (in a ClinicalTrials.gov record label) |
| ATO-OXY | Atomoxetine-oxybutynin |
| Ato75 | Atomoxetine 75 mg |
| ATS | American Thoracic Society |
| AUC | Area under the plasma concentration-time curve |
| AUCinf | Area under the plasma concentration-time curve extrapolated to infinity |
| AUClast | Area under the plasma concentration-time curve to the last measurable concentration |
| BID | Twice daily |
| BMI | Body mass index |
| BP | Blood pressure |
| BPAP | Bilevel positive airway pressure |
| CAD | Coronary artery disease |
| CE | Conformité Européenne |
| CENTRAL | Cochrane Central Register of Controlled Trials |
| CHIP | Children's Health Insurance Program |
| CI | Confidence interval |
| CL | Confidence limit |
| Cmax | Maximum plasma concentration |
| CMC | Chemistry, manufacturing, and controls |
| CMOs | Contract manufacturing organizations |
| CMS | Centers for Medicare & Medicaid Services |
| CNS | Central nervous system |
| COMISA | Comorbid insomnia and obstructive sleep apnea |
| COVID-19 | Coronavirus disease 2019 |
| CPAP | Continuous positive airway pressure |
| CPG | Clinical practice guideline |
| CrCl | Creatinine clearance |
| CRO | Contract research organization |
| CSSA | Cocaine Selective Severity Assessment |
| CV | Cardiovascular |
| CVD | Cardiovascular disease |
| CYP | Cytochrome P450 |
| CYP1A2 | Cytochrome P450 1A2 |
| CYP2C9 | Cytochrome P450 2C9 |
| CYP2D6 | Cytochrome P450 2D6 |
| CYP3A | Cytochrome P450 3A |
| CYP3A4 | Cytochrome P450 3A4 |
| D&E | Diet and exercise |
| DALY | Disability-adjusted life year |
| DMC | Data monitoring committee |
| DME | Durable medical equipment |
| DOA | Duration of approval |
| DORAs | Dual orexin receptor antagonists |
| DSM-5 | Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition |
| DSST | Digit Symbol Substitution Test |
| ECG | Electrocardiogram |
| EDS | Excessive daytime sleepiness |
| EEG | Electroencephalography |
| EMG | Electromyography |
| EOG | Electrooculography |
| EOS | End of study |
| ER | Emergency room; extended release |
| ERS | European Respiratory Society |
| ES | Excessive sleepiness |
| ESKD | End-stage kidney disease |
| ESS | Epworth Sleepiness Scale |
| FAQs | Frequently asked questions |
| FAS | Full Analysis Set |
| FDA | U.S. Food and Drug Administration |
| FOSQ | Functional Outcomes of Sleep Questionnaire |
| GIRK | G-protein-coupled inwardly rectifying potassium |
| GLP-1 | Glucagon-like peptide-1 |
| GLP-1 RA | Glucagon-like peptide-1 receptor agonist |
| GMR | Geometric mean ratio |
| HB | Hypoxic burden (based on 4% desaturation) |
| HB4 | Hypoxic burden based on 4% desaturation |
| HbA1c | Glycated hemoglobin (hemoglobin A1c) |
| HCU | Health care utilization |
| HGNS | Hypoglossal nerve stimulation |
| HI | Hepatic insufficiency |
| HMN | Hypoglossal motor nucleus |
| HNS | Hypoglossal nerve stimulation |
| HR | Hazard ratio |
| HRQoL | Health-related quality of life |
| HSAT | Home sleep apnea testing |
| HST | Home sleep test |
| ICER | Incremental cost-effectiveness ratio |
| ICSD-3 | International Classification of Sleep Disorders, Third Edition |
| ICSD-3-TR | International Classification of Sleep Disorders, Third Edition, Text Revision |
| ID | Identifier |
| IMP | Investigational medicinal product |
| INB | Incremental net benefit |
| INBp | Pooled incremental net benefit |
| IND | Investigational new drug application |
| IPD | Individual participant data |
| IPTW | Inverse probability of treatment weighting |
| IQR | Interquartile range |
| ISAACC | Impact of Sleep Apnea Syndrome in the Evolution of Acute Coronary Syndrome |
| ITT | Intent-to-treat |
| LG1 | Loop gain |
| LOCF | Last observation carried forward |
| LS | Least squares |
| MACCE | Major adverse cardiac or cerebrovascular events |
| MACE | Major adverse cardiovascular events |
| MACRA | Medicare Access and CHIP Reauthorization Act of 2015 |
| MAD | Mandibular advancement device |
| MAOI | Monoamine oxidase inhibitor |
| MCI | Mild cognitive impairment |
| MD | Mean difference |
| MI | Myocardial infarction |
| MIPA | Membership Interest and Asset Purchase Agreement |
| MIPS | Merit-based Incentive Payment System |
| mITT | Modified intention-to-treat |
| MMO | Maxillo-mandibular osteotomy |
| MMRM | Mixed model for repeated measurements |
| MNAR | Missing not at random |
| MrOS | Osteoporotic Fractures in Men Study |
| MTD | Maximum tolerated dose |
| MVC | Motor vehicle collision |
| N1 | Non-rapid eye movement sleep stage 1 |
| N2 | Non-rapid eye movement sleep stage 2 |
| N3 | Non-rapid eye movement sleep stage 3 |
| NCT | National Clinical Trial (ClinicalTrials.gov identifier) |
| NDA | New Drug Application |
| NHANES | National Health and Nutrition Examination Survey |
| NHATS | National Health and Aging Trends Study |
| NREM | Non-rapid eye movement |
| NRI | Norepinephrine reuptake inhibitor |
| NSF | National Sleep Foundation |
| NYSE | New York Stock Exchange |
| OA | Oral appliance |
| OAHI | Obstructive apnea-hypopnea index |
| ODI | Oxygen desaturation index |
| ODI3 | Oxygen desaturation index based on 3% desaturation |
| ODI4 | Oxygen desaturation index based on 4% desaturation |
| OLE | Open-label extension |
| OR | Odds ratio |
| OSA | Obstructive sleep apnea |
| OTC | Over-the-counter |
| PAP | Positive airway pressure |
| PAT | Peripheral arterial tonometry |
| PBO | Placebo |
| PDUFA | Prescription Drug User Fee Act |
| PFAS | Primary Full Analysis Set |
| PGI-C | Patient Global Impression of Change |
| PGI-S | Patient Global Impression of Severity |
| PK | Pharmacokinetics |
| PLM | Periodic limb movement |
| PPS-A | Per Protocol Set for AHI4 |
| PQRS | Physician Quality Reporting System |
| PRO | Patient-reported outcome |
| PROMIS | Patient-Reported Outcomes Measurement Information System |
| PROMIS-F | PROMIS Fatigue |
| PROMIS-SI | PROMIS Sleep Impairment |
| PROMs | Patient-reported outcome measures |
| PRSA | Physician-reported sleep apnea |
| PSG | Polysomnography |
| PVT | Psychomotor Vigilance Test |
| QALY | Quality-adjusted life year |
| QD | Once daily |
| QoL | Quality of life |
| QQ | Quantity and Quality of Work scale |
| QTc | QT interval corrected for heart rate |
| RCT | Randomized controlled trial |
| RDI | Respiratory disturbance index |
| REI | Respiratory event index |
| REI4 | Respiratory event index with hypopneas defined by 4% oxygen desaturation |
| REM | Rapid eye movement |
| REML | Restricted maximum likelihood |
| RERAs | Respiratory effort-related arousals |
| RICCADSA | Randomized Intervention With CPAP in Coronary Artery Disease and Sleep Apnea |
| RR | Relative risk |
| SAE | Serious adverse event |
| SaO2 | Arterial oxygen saturation |
| SAP | Statistical analysis plan |
| SAQLI | Sleep Apnea Quality of Life Index |
| SAS | Sleep apnea syndrome |
| SASS | Shionogi-Apnimed Sleep Science, LLC |
| SAVE | Sleep Apnea Cardiovascular Endpoints |
| SD | Standard deviation |
| SDB | Sleep-disordered breathing |
| SE | Standard error |
| SF-36 | 36-Item Short Form Health Survey |
| SF-6D | Short Form 6-Dimension |
| SHHS | Sleep Heart Health Study |
| SMUs | Single motor units |
| SNRIs | Selective norepinephrine reuptake inhibitors |
| SpO2 | Oxygen saturation (pulse oximetry) |
| SR | Systematic review |
| SS | Safety Set |
| STAR | Stimulation Therapy for Apnea Reduction |
| STOP | Snoring, Tiredness, Observed apnea, and high blood Pressure (screening questionnaire) |
| SWD | Shift work disorder |
| T2D | Type 2 diabetes |
| T90 | Time spent during sleep with oxygen saturation below 90% |
| TBT | Tennis ball technique |
| TCAs | Tricyclic antidepressants |
| TE | Treatment emergent |
| TEAE | Treatment-emergent adverse event |
| TF | Task Force |
| Tmax | Time to maximum plasma concentration |
| TST | Total sleep time |
| UC | Usual care |
| UI | Uncertainty interval |
| UK | United Kingdom |
| US | United States |
| USA | United States of America |
| V2 | Visit 2 |
| V3 | Visit 3 (randomization visit) |
| V4 | Visit 4 |
| VA/DoD | U.S. Department of Veterans Affairs and Department of Defense |
| VBA | Visual Basic for Applications |
| VOLT | Visual Object Learning Task |
| WASO | Wake after sleep onset |
| WHO | World Health Organization |

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
